Maciej J. Zamek-Gliszczynski, Ph.D.
Affiliations: | 2006 | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
PharmacologyGoogle:
"Maciej Zamek-Gliszczynski"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Kim L.R. Brouwer | grad student | 2006 | UNC Chapel Hill | |
| (Mechanisms of hepatic transport of sulfate and glucuronide metabolites.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Galetin A, Brouwer KLR, Tweedie D, et al. (2024) Membrane transporters in drug development and as determinants of precision medicine. Nature Reviews. Drug Discovery |
| Barth A, Perry CR, Shabbir S, et al. (2023) Clinical Assessment of Gepotidacin (GSK2140944) as a Victim and Perpetrator of Drug-Drug Interactions via CYP3A Metabolism and Transporters. Clinical and Translational Science |
| Taskar KS, Yang X, Neuhoff S, et al. (2022) Clinical relevance of hepatic and renal P-gp/BCRP inhibition of drugs: An International Transporter Consortium perspective. Clinical Pharmacology and Therapeutics |
| Zamek-Gliszczynski MJ, Sangha V, Shen H, et al. (2022) Transporters in drug development: International transporter consortium update on emerging transporters of clinical importance. Clinical Pharmacology and Therapeutics |
| Unger MS, Schumacher L, Enzlein T, et al. (2020) Direct Automated MALDI Mass Spectrometry Analysis of Cellular Transporter Function: Inhibition of OATP2B1 Uptake by 294 Drugs. Analytical Chemistry. 92: 11851-11859 |
| Zamek-Gliszczynski MJ, Patel M, Yang X, et al. (2020) Intestinal P-gp and Putative Hepatic OATP1B Induction: ITC Perspective on Drug Development Implications. Clinical Pharmacology and Therapeutics |
| Unger MS, Mudunuru J, Schwab M, et al. (2019) Clinically-relevant OATP2B1 inhibitors in marketed drug space. Molecular Pharmaceutics |
| Patel M, Eberl HC, Wolf A, et al. (2019) Mechanistic basis of cabotegravir-glucuronide disposition in humans. The Journal of Pharmacology and Experimental Therapeutics |
| Zamek-Gliszczynski MJ, Zhang X, Mudunuru J, et al. (2019) Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| Zamek-Gliszczynski MJ, Taub ME, Chothe PP, et al. (2018) Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clinical Pharmacology and Therapeutics |